Actinium (NYSE: $ATNM) Announces Initiation of Phase 2 Clinical Trial of Actimab-A in Patients Newly Diagnosed with Acute Myeloid Leukemia Over Age 60

Actinium (NYSE: $ATNM) Announces Initiation of Phase 2 Clinical Trial of Actimab-A in Patients Newly Diagnosed with Acute Myeloid Leukemia Over Age 60

Webinar to be held at 9:00 AM ET to highlight Actimab-A Phase 2 clinical trial and protocol revisions agreed to by the FDA

Protocol revisions agreed to by the FDA include the use of peripheral blast burden as an inclusion criteria, the mandated use of Hydroxyurea in patients with high peripheral blast burden and the elimination of low dose cytarabine

Trial will enroll 53 patients in a multicenter, open-label study designed to evaluate patient complete response rates and overall survival

NEW YORK - September 27, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company has initiated a Phase 2 clinical trial of Actimab-A in patients newly diagnosed with Acute Myeloid Leukemia (AML) who are over the age of 60. Actimab-A, Actinium's most advanced alpha particle immunotherapy (APIT) program consists of the CD33 targeting monoclonal antibody, HuM195, and the alpha-emitting radioisotope, actinium-225.

"We are excited to have initiated the Phase 2 trial of Actimab-A for elderly patients who are newly diagnosed with AML and ineligible for 7+3 treatment. These older patients face a poor prognosis and have limited viable treatment options" said Sandesh Seth, Actinium's Executive Chairman. "We are encouraged by the safety and efficacy signals we have seen thus far and look forward to the execution of this trial with an eye toward interim and top-line results which are both expected in 2017."

This Phase 2 clinical trial is a multicenter, open-label study that will enroll 53 patients. Patients will receive 2.0 µCi/kg/fractionated dose of Actimab-A via two injections given at day 1 and day 7. The Phase 2 trial is designed to evaluate complete response rates at up to day 42 after Actimab-A administration, where complete response is defined as complete remission (CR) or complete remission with incomplete platelet recovery (CRp). A formal interim analysis is expected to occur in mid-2017 with topline results expected in the second half of 2017. The Phase 2 trial will include peripheral blast burden as an inclusion criteria and in patients with high peripheral blast (PB) burden, the use of Hydroxyurea will be mandated with the goal of bringing PB burden below a key threshold number that the Company has identified from two previously complete Phase 1 clinical trials totaling 38 patients. In addition, the use of granulocyte colony-stimulating factors (GCSF) will be mandated. Low dose cytarabine has been eliminated from the protocol and the Phase 2 clinical trial will evaluate Actimab-A as a monotherapy. The secondary endpoint of the Phase 2 trial will be overall survival.

Dr. Joseph Jurcic, Principal Investigator of the Actimab-A Phase 2 trial and Director of Hematologic Malignancies; Professor of Medicine at Columbia University Medical Center said, "Actimab-A has been studied in two clinical trials thus far in patients with AML ranging in age from 18-87 who had a wide array of genetic risk factors that were at various stages of disease progression. Actimab-A has shown a promising safety and efficacy profile thus far that we believe differentiates Actimab-A from other CD33 targeting drug candidate, which is an exciting space in AML. Our PB burden hypothesis indicates that of all factors related to AML including age, stage of disease and genetic factors, peripheral blast burden showed to be the most relevant. With PB burden serving as an inclusion criteria in this Phase 2 trial and the use of Hydroxyurea being mandated in patients with PB burden above a key threshold we look forward to conducting this clinical trial in this older patient population that has a great unmet medical need."

The Company will host a webinar Tuesday, September 27, 2016 at 9:00 AM ET to discuss the Phase 2 clinical trial. Details for the webinar are as follows:

Date: Tuesday, September 27, 2016 
Time: 9:00 AM ET 
Webinar Link: https://onecast.thinkpragmatic.com/ses/awQiM-9OD7Iysoul6ZD6BQ~~ 
Speakers: Joseph Jurcic, M.D., Director of Hematologic Malignancies; Professor of Medicine at Columbia University Medical Center
Actimab-A Principal Investigator 
Sandesh Seth, Executive Chairman, Actinium Pharmaceuticals 
Dragan Cicic, M.D., Chief Medical Officer, Actinium Pharmaceuticals

Read this release in full at http://www.investorideas.com/CO/ATNM/news/2016/09271Actimab-A.asp

About Actimab-A

Actimab-A, Actinium's most advanced alpha particle immunotherapy (APIT) program, is being prepared for a Phase 2 clinical trial for patients newly diagnosed with AML over the age of 60. Actimab-A is being developed as a first-line therapy and it has attracted support from some of the leading experts at the most prestigious cancer treatment hospitals due to the potential of its safety and efficacy profile. Actimab-A consists of the monoclonal antibody, HuM195, and the radioisotope, actinium-225. Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. HuM195 is the humanized version of M195 and is a monoclonal antibody that targets CD33, which is abundantly found on myeloid leukemia cells. Both the alpha particle technology and HuM195 were initially developed at Memorial Sloan Kettering Cancer Center. Actimab-A is a second-generation therapy from the Company’s HuM195-Alpha program, which has now been studied in almost 90 patients in four clinical trials.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is in a 53 patient, multicenter, open-label Phase 2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Steve O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com

Source: Actinium Pharmaceuticals

Visit this company: www.actiniumpharma.com

More info on ATNM at Investorideas.com Visit: http://www.investorideas.com/CO/ATNM/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp.

Disclosure: One month news , social media and marketing Actinium Pharmaceuticals, Inc. (ATNM) by third party IRTH Communications starting September 19, 2016: three thousand per month.

Actinium Pharmaceuticals (NYSE: $ATNM) to Sponsor and Participate in Be The Match® Walk+Run to Raise Awareness for Bone Marrow Transplant

Actinium Pharmaceuticals (NYSE: $ATNM) to Sponsor and Participate in Be The Match® Walk+Run to Raise Awareness for Bone Marrow Transplant

NEW YORK - September 26, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company has sponsored and will participate in the upcoming Be The Match® Walk+Run being held on Saturday, October 1, 2016, at Firefighter's Field on Roosevelt Island, New York, New York. The goal of the Walk+Run is to raise awareness for bone marrow transplant (BMT), raise funds to help transplant patients, support marrow transplant research and add more potential marrow donors to the Be The Match Registry®.

Employees of Actinium Pharmaceuticals, together with their family and friends, will be participating in the Be The Match® Walk+Run to raise awareness and funds. To support Team Actinium and Be The Match® , please visit Actinium's team page here: Click here to view the team page for Team Actinium

"Actinium is focused on developing products which may improve the lives of patients with leukemia, lymphoma or one of the many other life-threatening diseases that could benefit from a bone marrow transplant," stated David Gould, M.D., Actinium's Senior Vice President of Corporate Development and Corporate Affairs. "Be The Match provides incredible support to these patients and we are honored to have the ability to sponsor such a worthwhile event and we are excited to participate in the Walk+Run on October first."

About Be The Match®

For people with life-threatening blood cancers—like leukemia and lymphoma—or other diseases, a cure exists. Be The Match connects patients with their donor match for a life-saving marrow or umbilical cord blood transplant. People can contribute to the cure as a member of the Be The Match Registry, financial contributor or volunteer. Be The Match provides patients and their families one-on-one support, education, and guidance before, during and after transplant.

Be The Match is operated by the National Marrow Donor Program® (NMDP), a nonprofit organization that matches patients with donors, educates health care professionals and conducts research so more lives can be saved. To learn more about the cure, visit BeTheMatch.org or call 1 (800) MARROW-2

Read this release in full at http://www.investorideas.com/CO/ATNM/news/2016/09261BoneMarrowTransplant.asp

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Steve O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com

Be the Match Foundation®
Melissa Neill
Strategic Public Relations Specialist
763-406-8762

Source: Actinium Pharmaceuticals

Visit this company: www.actiniumpharma.com

More info on ATNM at Investorideas.com Visit: http://www.investorideas.com/CO/ATNM/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp.

Disclosure: One month news , social media and marketing Actinium Pharmaceuticals, Inc. (ATNM) by third party IRTH Communications starting September 19, 2016: three thousand per month.

Sector News Snapshot; #Mining in Mexico; (TSX: $EDR), (TSXV: $GNC), (TSX: $PAA), (TSXV: $SIL.V)

Sector News Snapshot; #Mining in Mexico; (TSX: $EDR), (TSXV: $GNC), (TSX: $PAA), (TSXV: $SIL.V)

Point Roberts, WA, Delta BC – September 23, 2016 – Investorideas.com, a global news source and investor resource issues a sector news snapshot for the mining sector. Recent news in September from companies currently mining in Mexico include Endeavour Silver Corp. (NYSE: EXK) (TSX: EDR), Gainey Capital Corp. (TSXV: GNC; OTCQX: GNYPF), Pan American Silver Corp. (NASDAQ: PAAS) (TSX: PAA) and SilverCrest Metals Inc. (TSXV: SIL.V).

Read this release in full at http://www.investorideas.com/news/2016/mining/09232Mexico.asp

Endeavour Silver Corp. (NYSE: EXK) (TSX: EDR) announced it entered into a definitive agreement dated September 13, 2016 (the "Agreement") with Silver Standard Resources Inc. to acquire a 100% interest in Silver Standard's Parral properties, located in the historic silver mining district of Hidalgo de Parral in southern Chihuahua state, Mexico.

Pursuant to the Agreement, Endeavour will pay US$6 million in Endeavour common shares, being 1,198,083 common shares at US$5.008 per share, representing the 10-day average closing price of Endeavour's shares on the New York Stock Exchange ("NYSE") prior to the date of the Agreement.

In addition, Endeavour has committed to spend US$2 million on exploration on two of the properties (the San Patricio and La Palmilla properties) over the two-year period following the closing of the transaction. Upon completing this exploration expenditure, Endeavour will have one year to deliver a National Instrument 43-101 ("NI 43-101") technical report, including a resource estimate, and issue an additional US$200,000 in common shares to Silver Standard for each one million ounces of silver delineated in measured and indicated resources on the San Patricio and La Palmilla properties, based on the 10-day average closing price of Endeavour's common shares on the NYSE prior to the earlier of delivery of the NI 43-101 report and the third anniversary of the initial closing date under the Agreement. Silver Standard will also retain a 1% net smelter returns royalty on production from the San Patricio and La Palmilla properties.

Gainey Capital Corp. (TSXV: GNC; OTCQX: GNYPF) recently reported that the Phase 1 Drilling campaign has completed the first three Diamond Drill holes at the El Colomo Gold-Silver Project in Mexico. The first of the three holes targeting the La Nueva Victoria Mineralized Zone has been sampled and shipped to ALS Labs Vancouver, BC for analysis and the other two holes are currently being processed at the Company’s core logging facility to be submitted shortly. Preliminary results from these drill holes are anticipated within the next few weeks.

Furthermore, the Company is pleased to announce that the program continues to advance with the commencement of drilling on the first of four targets at the La Higuerita/El Arrayan Mineralized Zones.

Gainey’s exploration team, led by Rafael Gallardo of Minera Cascabel S.A. de C.V., notes that though they have encountered two serious weather systems in the region, the program has not met any serious delays, and drilling progress has continued on the target zones. David Coburn, CEO of Gainey, commented, "we are looking forward to the first set of drilling results over the next 2-3 weeks. The Exploration Team has done an excellent job meeting their objectives given they have encountered challenging weather conditions."

The Company recently upgraded its exploration team with the addition of David Hladky, P.Geo. to the Technical Advisory Board, who is also the Company’s acting Qualified Person as defined by NI 43-101, please see the Company’s news release on July 26, 2016 for full details. Mr. Hladky’s previous position was with Cayden Resources Inc. as the Qualified Person and one of the leaders in the exploration of the Morelos Sur and El Barqueno projects in Mexico, that were successfully sold to Agnico Eagle Mines for $205 Million in 2014.

Pan American Silver Corp. (NASDAQ: PAAS) (TSX: PAA) announced that it achieved important milestones at its two mine expansion projects currently underway in Mexico. At the Company's La Colorada mine, the new 618-metre deep shaft was commissioned in fully automatic mode in early September, ahead of schedule. The shaft was constructed with a world-class safety performance of zero lost-time accidents incurred and using industry-leading raise boring and shaft automation technologies. The work remaining to complete the La Colorada expansion project includes a new filter plant, power line and underground development. The project is now expected to be completed approximately 5 to 10 percent under budget.

At the Company's Dolores mine, the new 98 kilometre, 115 kV power line that connects the mine to the national power grid was energized in early September. The new power line was completed on budget and is expected to result in annual savings of about $9 million.

"We successfully achieved these milestones on or under budget and funded them entirely from internal resources," said Michael Steinmann, President and CEO. "These expansion projects will contribute to higher production rates and lower costs at both operations, and as silver prices rise, our shareholders are positioned to benefit from widening profit margins."

The La Colorada expansion project commenced in 2014 with an original capital investment estimate of about $163.8 million, including sustaining capital. By the end of 2017 when the project is expected to be completed, processing rates are expected to increase to 1,800 tonnes per day, resulting in a 69 percent increase in annual silver production to approximately 7.7 million ounces.

The Dolores expansion project has an estimated capital investment of approximately $112.4 million. By the end of 2017, this project is expected to increase annual silver production by about 40 percent to 6.3 million ounces and gold production by about 52 percent to over 205,000 ounces.

SilverCrest Metals Inc. (TSXV: SIL.V) announced the results of the remaining drill holes from Phase I drilling for the Las Chispas Project. The Las Chispas Project ("Las Chispas") is located in Sonora State, Mexico and is in a historic silver-gold mining district which presently hosts two nearby precious metal producers. Historic information indicates that of the fourteen historically reported veins at Las Chispas, only three veins, the Las Chispas, William Tell and Babicanora, had documented production, which occurred between 1880 and 1930. SilverCrest’s initial focus is on these three veins. To the Company’s knowledge, none of the known veins have been drilled prior to the Company’s Phase I drill campaign. For more information, please refer to our website at http://www.silvercrestmetals.com.

Dunham Craig, P.Geo., Interim CEO remarked, "The remaining drill hole results from the Phase I drill program intercepted the Las Chispas vein which has further demonstrated continuity of high grades and potential mineable thicknesses. Phase II exploration work will continue to define the Las Chispas vein for resource estimation expected in H1 2017. As we continue to systematically explore this district-wide discovery with multiple undrilled epithermal veins, we could potentially have several more discoveries. The Babicanora area (no previous drilling), immediately adjacent to Las Chispas and William Tell veins, is considered the largest target in the district and will be tested in Phase II exploration."

Full news - http://www.investorideas.com/CO/SILV/news/2016/09141DrillingConfirms.asp

About Investorideas.com - News that Inspires Big Ideas

Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Follow stocks in your favourite stock sector with Investor Ideas stock directories

http://www.investorideas.com/membership/

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.  Disclosure- Gainey Capital Corp retained Investorideas.com for news and social media for 3 months – SilverCrest Metals Inc.is an  annual news publication client on Investorideas - see details http://www.investorideas.com/About/News/Clientspecifics.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com

800-665-0411

#Tech Stocks Added: $SYNC, $AIF.TO, $IMI, $ITRN, $LIOX, $MXPT, $PERI, $TISA, $UNXL, $TTD, Tel Aviv:ALMO.TA and CSE:NUR

#Tech Stocks Added: $SYNC, $AIF.TO, $IMI, $ITRN, $LIOX, $MXPT, $PERI, $TISA, $UNXL, $TTD, Tel Aviv:ALMO.TA and CSE:NUR

Point Roberts, WA, Delta BC – September 23, 2016 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its global stock directories within technology, mining, beverage and cannabis.

Companies added in the tech sector include cloud computing, software, semiconductor, internet advertising, and wireless stocks that trade on the Tel Aviv, Canadian and NASDAQ exchanges.

Also within the tech sector is a new listing in one of our fastest growing sub-sectors: GPS and Tracking Devices - Ituran Location & Control Ltd. (NASDAQGS: ITRN).  Ituran provides location-based services, consisting predominantly of stolen vehicle recovery and tracking services, as well as wireless communications products used in connection with its location-based services and various other applications. Ituran offers mobile asset location, Stolen Vehicle Recovery, management & control services for vehicles, cargo and personal security.

New Mining Companies all trade on the TSX Venture Exchange and the latest addition to our cannabis list is Vitality Biopharma, Inc. (OTC:VBIO) which is looking to cannabinoids for the treatment of serious neurological and inflammatory disorders. 

Added to our Food and Beverage Stocks List is Craft Beer Company, Evans Brewing Company Inc. (OTC:ALES) which develops and distributes premium award-winning craft brands and has future plans that include the opening of the company's first restaurant/taproom, The Public House by Evans Brewing Company.

Read full release: http://www.investorideas.com/news/2016/technology/09231Stocks.asp

Technology Companies Added:

Synacor, Inc. (NasdaqGM:SYNC), Altus Group Ltd. (TSX:AIF.TO), Algomizer, Ltd. (Tel Aviv: ALMO.TA),  Intermolecular, Inc. (NasdaqGS: IMI),  Ituran Location & Control Ltd. (NASDAQGS: ITRN), Lionbridge Technologies Inc. (NasdaqGS: LIOX), MaxPoint Interactive, Inc. (NasdaqGM:MXPT), NuRAN Wireless Inc. (CSE: NUR), Perion Network Ltd. (NasdaqGS:PERI), Top Image Systems Ltd. (NasdaqCM:TISA), UniPixel, Inc. (NasdaqCM: UNXL) and Trade Desk, Inc., The (NasdaqGM:TTD)    

Mining Companies Added:

Ashanti Gold Corp. (TSX:AGZ.V), Sienna Resources Inc (TSX:SIE.V; OTC: SNNAF),   Inovent Capital Inc. (TSX: IVQ-P.V) and Alset Energy Corp. (TSX:ION.V)

Cannabis/Biotech Stock Added:

Vitality Biopharma, Inc. (OTC:VBIO) is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders.

Beverage Stock Added:

Evans Brewing Company Inc. (OTC:ALES) develops and distributes premium craft brands including a superior line of lagers and ales that have been honored with over 20 international awards. Operating the oldest brewery in Orange County, California, Evans Brewing supplies restaurants, retailers and beer drinkers across several states. Future plans include the opening of the company's first restaurant/taproom, The Public House by Evans Brewing Company, broader product distribution, and potentially an expansion of the beer brands currently under management.

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas

Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:

From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

http://www.investorideas.com/membership/

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com

800-665-0411

Cyprium Mining (TSX: $CUG.V) Debenture Holders Approve Extension Of Maturity Date To February 28th, 2019

Cyprium Mining (TSX: $CUG.V) Debenture Holders Approve Extension Of Maturity Date To February 28th, 2019

All other matters presented at debenture holders meeting also approved

Montreal - September 22, 2016 (Investorideas.com Newswire) Cyprium Mining Corporation ("Cyprium" or the "Company") (TSX-V: CUG and CUG.DB) is pleased to announce that at a special meeting of debenture holders held on September 21 st, 2016 (the "Meeting") the holders of $750,000 in principal amount of unsecured debentures bearing interest at 12% per annum (the "Debentures") overwhelmingly approved all matters presented, including the extension of the maturity date from February 28 th, 2017 to February 28 th, 2019. The Corporation had issued the Debentures under a debenture indenture dated February 28, 2014 (the "Indenture"). The Debentures were entitled to be voted at the Meeting on the basis of one vote for each one dollar of principal amount.

The matters approved at the Meeting are to: (i) authorize CST Trust Company, as debenture trustee, to grant an extension of time for payment of principal on the Debentures from February 28th, 2017 to February 28th, 2019 , (ii) amend the Indenture to allow past due and future interest to be payable through the issuance of common shares in the capital of the Corporation (the "Common Shares"), (iii) amend the Indenture to allow for conversion of the principal amount and any accrued and unpaid interest of the Debentures into Common Shares, the option of the holder, at a price per Common Share equal to $0.10 before February 28th, 2017 and $0.15 thereafter; (iv) approve the delisting of the Debentures from the TSX Venture Exchange; and (v) waive any past defaults, and direct the debenture trustee to waive any past defaults, on the part of the Corporation in complying with any and all provisions of the Indenture.

The Corporation is also pleased to announce that it has extended the maturity of US $1,026,000 of 12.5% bonds from March 15 th, 2018 to January 1 st, 2019 (the "Bonds"). The Bonds were issued as part of the bond financing announced by Cyprium in March 2015 . As part of the amendment of the Bonds, the Corporation was granted the option to pay all interests in common shares of the Corporation.

Alain Lambert , Chairman and CEO of Cyprium commented: "I'm glad to report that 96.8% of the principal amount of debentures voted at the meeting were in favour of all matters presented. This sends a clear message of support for the company's business plan. Our objective remains to finalize in the next two weeks further extensions of the maturity date of various loans so that at least 90% of the company's loans will mature in 2019. Achieving this objective will pave the way for greater access to the equity market as well as possible corporate transactions to ensure the development of the Potosi mine and the La Chinche exploration property."

Read this release in full at http://www.investorideas.com/CO/CUG/news/2016/09221MaturityDate.asp

About Cyprium Mining Corporation

For further information, please contact:

Alain Lambert, Chairman and C.E.O.
ir@cypriummining.com

Ron Keenan, C.O.O.
rkeenan@cypriummining.com
Phone + 1 514 915 3836

www.cypriummining.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains "forward-looking information" (within the meaning of applicable Canadian securities laws) and "forward -looking statements" (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995). Such statements or information are identified with words such as "anticipate", "believe", "expect", "plan", "intend", "potential", "estimate", "propose", "project", "outlook", "foresee" or similar words suggesting future outcomes or statements regarding an outlook. Such statements include, among others, those concerning the Company's anticipated plans for developments of the Company and its mining projects".

Such forward-looking information or statements are based on a number of risks, uncertainties and assumptions which may cause actual results or other expectations to differ materially from those anticipated and which may prove to be incorrect. Assumptions have been made regarding, among other things, management's expectations regarding future growth, plans for and completion of projects by Company's third party relationships, availability of capital, and the necessity to incur capital and other expenditures. Actual results could differ materially due to a number of factors, including, without limitation, operational risks in the completion of Company's anticipated projects, delays or changes in plans with respect to the development of Company's anticipated projects by Company's third party relationships, risks affecting the ability to develop projects, risks inherent in operating in foreign jurisdictions, the ability to attract key personnel, and the inability to raise additional capital. No assurances can be given that the efforts by the Company will be successful. Additional assumptions and risks are set out in detail in the Company's MD&A, available on SEDAR at www.sedar.com.

Although the Company believes that the expectations reflected in the forward-looking information or statements are reasonable, prospective investors in the Company's securities should not place undue reliance on forward-looking statements because the Company can provide no assurance that such expectations will prove to be correct. Forward-looking information and statements contained in this news release are as of the date of this news release and the Company assumes no obligation to update or revise this forward-looking information and statements except as required by law. Investors should note that the Potosi silver mine and La Chinche property have no established mineral resources or mineral reserves as defined by NI 43-101. Although Cyprium Mining has made a production decision regarding the Potosi silver mine based on historical production records and results from recent sampling, a feasibility study of its projects has not been completed and there is no certainty that the proposed operations will be economically or technically viable.

SOURCE Cyprium Mining Corporation

Visit this Company: www.cypriummining.com    

More info on CUG.V at Investorideas.com:http://www.investorideas.com/CO/CUG/

Sign up for the free investor news and stock alerts:

http://www.investorideas.com/Resources/Newsletter.asp

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Cyprium Mining Corporation: six month news, PR and social media mining program for 9700 starting August 12, 2016

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Gopher Protocol (OTCQB: $GOPH) Introduces Its Guardian Sphere

Gopher Protocol (OTCQB: $GOPH) Introduces Its Guardian Sphere

SAN DIEGO, CA - September 21, 2016 (Investorideas.com Newswire) Gopher Protocol Inc. (OTCQB:GOPH) ("Gopher" and the "Company"), a development-stage company which specializes in the development of real-time, heuristic-based mobile technologies, and its partner Guardian Patch LLC, announced today that they are currently ramping-up efforts for the release of their Guardian Sphere tracking device, which is primarily designed for pets, but may also be used for tracking children, adults, including the disabled, inventory, artwork, or virtually any object located within an area covered by the device.

The Guardian Sphere (the "Sphere") system is a derivative technology of the Company's Guardian Patch technology. The Sphere is designed to provide its users with local tracking capability using a re-chargeable/replaceable battery source. The Sphere is an innovative tracking device that can easily be attached to a pet's collar and then transmit real-time location information to the smartphone(s) or website account of the registered owner of the device. The Sphere has a replaceable battery and operates on the exclusive Guardian private network which provides owners with the unique ability to obtain real-time tracking information without the need for GPS, Wi-Fi or cellular service.

The Sphere includes state of the art radio technology, a GPS system and micro controller systems. It sends signals in specific intervals to report on its location. The system analyzes the information using its proprietary, advanced mathematical modeling software that precisely calculates the Sphere's location. The mobile application then presents the exact location of the Sphere on the map. An additional unique system feature is its own Emergency Alert system. The user has the ability to transmit an emergency alert on his or her Sphere's location, directly from the mobile app. All registered users located in that Sphere's proximity will be notified about the Emergency and may notify the user about the Sphere's recovery (which we fondly refer to as a "private emergency alert"). The Sphere utilizes is a bi-directional system which enables data transmission/receiving acknowledgment. It also includes error correction protocol to ensure data accuracy. The Sphere has its own battery source and may be plugged to external power using standard Android type charger socket. The Sphere comes with its own ID. This ID is registered on the mobile app to track the Sphere's location. Multiple Spheres can be registered on the same app for multiple tracking. It is an ideal tracking device for personal and commercial purposes for those seeking high-performance local tracking at an affordable price.

The Sphere represents the Company's entry into the burgeoning global pet wearable market, which is expected to reach USD 2.36 billion by 2022 according to a press release[1] issued by Grand View Research, Inc. in February 2016. According to Grand View's press release, "Growing pet ownership coupled with increasing per capita expenditure on pets is expected to drive product demand over the forecast period." In addition, as stated in a press release[2] issued by the Insurance Information Institute, according to the 2015-2016 National Pet Owners Survey conducted by the American Pet Products Association (APPA), Sixty-five percent of U.S. households, or about 79.7 million families, own a pet, which is up from 56 percent of U.S. households in 1988, the first year the survey was conducted. The Company believes that the above information suggests a significant potential market for the Sphere and one that the Company believes could potentially benefit from the Sphere.

"The current demand for GPS-based devices that are capable of providing real-time positioning of our loved ones and valuables is fueling global advancements in technologies which are enabling people to remain connected to the things that they value most. In millions of households across the world, pets are beloved members of the family. Our goal in developing the Sphere is to provide pet owners with peace of mind through the use an invaluable recovery tool which will enable them to track their pets in real-time should they ever become separated," stated Company CEO Michael Murray.

In addition to operating as a tracking device for household pets, the Company also recognizes an opportunity for the Sphere to be utilized for tracking valuable livestock on farms as well as animals registered as endangered species.

At the time of this press release, the Company has not specified a release date for the Sphere. The Company is committed to providing more definitive release date information in the coming weeks and is targeting a release date of approximately Q1 2017, of which there is no guarantee.

Read this release in full at http://www.investorideas.com/CO/GOPH/news/2016/09211GuardianSphere.asp

About Guardian Patch

The Guardian Patch (the "Patch"), potentially arriving in consumer markets in 2017, is a unique location technology that works with or without GPS. The Patch is a "stick-on" device that provides its users with the capability to protect and track objects, a loved-one or even a pet, through a mobile application. Download the Patch app, register your patch, and track anything that you own on your mobile device or on our designated website. Register the Patches of your family members and friends to receive alerts in the event of an emergency. Peel the Patch off and the Patch acts as a beacon, sending out a signal and notifying anyone who has registered the user's Patch.

About Gopher Protocol Inc.

Gopher Protocol Inc. (OTCQB: GOPH) (“Gopher” and the "Company") (http://gopherprotocol.com/) is a development-stage company developing a real-time, heuristic-based mobile technology.  Upon development, the technology will consist of a smart microchip, mobile application software and supporting software that will run on a server.  The system contemplates the creation of a global network.  Gopher believes this will be among the first system that is developed using a human, heuristic-based analysis engine.  Since the core of the system will be its advanced microchip technology that will be capable of being installed in any mobile device worldwide, Gopher expects that this will result in an internal, private network between all mobile devices utilizing the microchip by providing mobile technology for computing power enhancement, advanced mobile database management/sharing and other additional mobile features.

Corporate Site: http://gopherprotocol.com

Press page/ press kit - http://gopherprotocol.com/?page_id=228

Consumer and product website for Guardian Patch: http://www.guardianpatch.com/

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements".  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes.  The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

[1] https://www.grandviewresearch.com/press-release/global-pet-wearable-market

[2] http://www.iii.org/fact-statistic/pet-statistics

Contact:

Danny Rittman CTO
Gopher Protocol Inc.
VM Only - 888-685-7336

Media: press@gopherprotocol.com

Visit this company: http://gopherprotocol.com/

More info on GOPH at Investorideas.com Visit: http://www.investorideas.com/CO/GOPH/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GOPH is a PR , social media and publishing client and compensates Investorideas.com ( three months effective April 4, 2016- three thousand five hundred per month )

More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.